ST
SRPT icon

Spot Trading’s Sarepta Therapeutics SRPT Stock Holding History

Spot Trading’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		$3.24M Hold
71,500
– – 0.06% 474
2017
Q2 		$2.41M Buy
71,500
+39,600
+124% +$1.29M 0.05% 559
2017
Q1 		$944K Sell
31,900
-800
-2% -$24.8K 0.03% 785
2016
Q4 		$897K Sell
32,700
-12,500
-28% -$502K 0.02% 1027
2016
Q3 		$2.78M Sell
45,200
-33,900
-43% -$1.02M 0.06% 489
2016
Q2 		$1.51M Buy
79,100
+44,400
+128% +$822K 0.03% 847
2016
Q1 		$677K Buy
34,700
+34,500
+17,250% +$603K 0.01% 1359
2015
Q4 		$8K Sell
200
-20,000
-99% -$648K ﹤0.01% 3359
2015
Q3 		$649K Sell
20,200
-1,500
-7% -$50.9K 0.01% 1869
2015
Q2 		$660K Buy
+21,700
New +$444K 0.01% 1918
2015
Q1 		– Sell
-34,100
Closed -$493K – 4299
2014
Q4 		$493K Sell
34,100
-2,600
-7% -$44K ﹤0.01% 2355
2014
Q3 		$774K Buy
36,700
+700
+2% +$15.8K ﹤0.01% 2257
2014
Q2 		$1.07M Sell
36,000
-2,100
-6% -$66.4K 0.01% 2084
2014
Q1 		$916K Buy
38,100
+38,000
+38,000% +$969K 0.01% 2083
2013
Q4 		$2K Hold
100
– – ﹤0.01% 3902
2013
Q3 		$5K Buy
+100
New +$3.85K ﹤0.01% 3960

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
TCP
Tourbillon Capital Partners New York $6.26M AUM 42.29% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Spot Trading's SRPT Position: Q3 2017 in Review

Spot Trading increased its Sarepta Therapeutics (SRPT) stake by 28% in Q3 2017, buying an estimated $428K and bringing the position to 48,931 shares worth $2.22M. The position accounts for 0.04% of the portfolio, ranked #672.

Spot Trading first reported a position in SRPT in Q1 2014 and has held it in 15 quarters since. The position peaked at $3.62M in Q3 2016. 233 funds tracked by Wall St. Rank hold SRPT as of Q3 2017.

  • Spot Trading held 48,931 shares of Sarepta Therapeutics worth $2.22M as of Q3 2017.
  • Spot Trading bought 10,706 Sarepta Therapeutics shares in Q3 2017, an estimated $428K.
  • Sarepta Therapeutics made up 0.04% of Spot Trading's portfolio in Q3 2017, its #672 holding.
  • Spot Trading first reported a position in Sarepta Therapeutics in Q1 2014 and has held it in 15 quarters since.
  • Spot Trading's Sarepta Therapeutics position peaked at $3.62M in Q3 2016.
  • 233 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2017.

Based on Spot Trading's 13F filing for Q3 2017, filed 6 Nov 2017.